ケモカイン受容体7ノックアウトは,動脈硬化性プラークの発達を弱める
Maren Luchtefeld1, Christina Grothusen, Andreas Gagalick
1Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
Circulation
|October 6, 2010
まとめ
ケモカイン受容体7 (CCR7) の全身的欠乏は,T細胞の移動とプライミングを阻害することによって,動脈硬化症の進行を減少させます. これは,CCR7を強調しています.
科学分野:
- 免疫学 免疫学とは
- 心血管研究 循環器科の研究
- 炎症性疾患 炎症性疾患とは
背景:
- 動脈硬化症は,プラーク形成を含む全身性炎症性疾患である.
- 生まれつきの免疫と適応免疫の両方がアテロゲネシスで役割を果たし,複雑な相互作用があります.
- ケモカイン受容体7 (CCR7) は,リンパ性臓器および炎症組織における免疫細胞の密輸に不可欠です.
研究 の 目的:
- 系統的なケモカイン受容体7 (CCR7) 欠乏がアテロゲネシスにおける役割を調査する.
- T細胞の移動に対するCCR7の影響と,LDLRノックアウトマウスにおける動脈硬化性プラークの形成への影響を決定する.
主な方法:
- 動脈硬化に弱い低密度リポプロテイン受容体 (ldlr) ノックアウトマウスを利用し,全身性CCR7欠乏症でした.
- CCR7欠乏したマウスの動脈硬化性プラーク発達の評価.
- 血管新生性病変におけるT細胞の行動 (入出) を研究し,ex vivo-primed T細胞と酸化低密度リポタンパク質 (oxLDL) による養子移植実験を用いた.
主要な成果:
- CCR7欠乏症は,動脈硬化性プラークの発生を著しく減少させました.
- CCR7欠乏性T細胞は,動脈硬化性病変の内外への移動が低下した.
- CCR7欠乏性T細胞ではなく,oxLDLでプリムされた野生型T細胞の養子移植により,受容体マウスのアテロゲネシスを再構成した.
結論:
- 二次リンパ性臓器内のCCR7依存のT細胞プライミングとCCR7媒介のT細胞再循環は,動脈硬化性プラークの進行において重要である.
- CCR7は,動脈硬化を引き起こす適応性免疫応答を調節する上で重要な役割を果たします.
関連する概念動画
Inflammation
46.8K
Overview
46.8K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747


